SRR1440876
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.456
- COAGULATION+0.440
- IL6_JAK_STAT3_SIGNALING+0.365
- INTERFERON_GAMMA_RESPONSE+0.360
- BILE_ACID_METABOLISM+0.326
- INFLAMMATORY_RESPONSE+0.322
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.251
- TNFA_SIGNALING_VIA_NFKB+0.248
- KRAS_SIGNALING_DN+0.242
- ALLOGRAFT_REJECTION+0.229
Top 10 suppressed
- MYC_TARGETS_V1-0.454
- UNFOLDED_PROTEIN_RESPONSE-0.408
- MYC_TARGETS_V2-0.376
- DNA_REPAIR-0.342
- MITOTIC_SPINDLE-0.326
- PROTEIN_SECRETION-0.314
- E2F_TARGETS-0.301
- MTORC1_SIGNALING-0.291
- G2M_CHECKPOINT-0.278
- PI3K_AKT_MTOR_SIGNALING-0.244
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1339968 | GTEX | — | 0.916 |
| 2 | SRR1334033 | GTEX | — | 0.914 |
| 3 | SRR1472150 | GTEX | — | 0.908 |
| 4 | SRR1375203 | GTEX | — | 0.903 |
| 5 | SRR1364739 | GTEX | — | 0.902 |
| 6 | SRR1389036 | GTEX | — | 0.899 |
| 7 | SRR818057 | GTEX | — | 0.897 |
| 8 | SRR1491293 | GTEX | — | 0.896 |
| 9 | SRR1345478 | GTEX | — | 0.893 |
| 10 | SRR607647 | GTEX | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.456 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.365 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.326 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.322 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.251 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.248 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.242 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.229 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.228 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.216 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.213 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.198 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.194 | Inavolisib | — uncovered |
| MYOGENESIS | 0.188 | Inavolisib | — uncovered |
| COMPLEMENT | 0.167 | Inavolisib | — uncovered |
| APOPTOSIS | 0.161 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.152 | Remibrutinib | — uncovered |